HDM1005 Clinical Trials (2026): 10 Studies for Obesity & Type 2 Diabetes
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
10 HDM1005 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 6 indications (including Obesity & Type 2 Diabetes) and 2,982 total planned enrollment. 3 Phase 3 HDM1005 trials and 3 Phase 2 are listed. 8 HDM1005 clinical trials are actively recruiting. Most recent activity: NCT07417306 (Dec 2027).
HDM1005 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | completed | not yet recruiting | Total |
|---|---|---|---|---|
| P1 | 2 | 2 | 4 | |
| P2 | 3 | 3 | ||
| P3 | 2 | 1 | 3 |
Recruiting HDM1005 clinical trials (8)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07417306 | SGLT2A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor | P3 | Type 2 Diabetes | 912 | Mar 2026 |
| NCT07394114 | A Study of HDM1005 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone | P3 | Type 2 Diabetes | 240 | Feb 2026 |
| NCT07521631 | Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes | P2 | Obesity | 372 | Mar 2026 |
| NCT07502001 | Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin | P1 | Overweight | 42 | Apr 2026 |
| NCT07279194 | Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes | P3 | Obesity & Overweight | 825 | Oct 2025 |
| NCT07559240 | A Pharmacokinetic Study of HDM1005 Injection in Participants With Impaired Renal Function and Healthy Participants | P1 | Overweight | 30 | May 2026 |
| NCT07109700 | A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin | P2 | Type 2 Diabetes | 216 | Apr 2025 |
| NCT06886126 | Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes Mellitus | P2 | Obesity | 240 | Feb 2025 |
HDM1005 clinical trials by indication
Type 2 Diabetes (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07417306 | SGLT2 | P3 | not yet recruiting | A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor |
| NCT07394114 | — | P3 | recruiting | A Study of HDM1005 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone |
| NCT07109700 | — | P2 | recruiting | A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin |
Overweight (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07502001 | — | P1 | not yet recruiting | Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin |
| NCT07559240 | — | P1 | not yet recruiting | A Pharmacokinetic Study of HDM1005 Injection in Participants With Impaired Renal Function and Healthy Participants |
Obesity (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07521631 | — | P2 | recruiting | Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes |
| NCT06886126 | — | P2 | recruiting | Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes Mellitus |
Obesity & Overweight (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07279194 | — | P3 | recruiting | Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes |
Overweight and Obesity (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06637020 | — | P1 | completed | Phase Ib Clinical Study of HDM1005 Injection |
Obesity and Overweight (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06640647 | — | P1 | completed | Phase Ia Clinical Study of HDM1005 Injection |
HDM1005 pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| SGLT2 | NCT07417306 | P3 | not yet recruiting | Type 2 Diabetes | 912 | — |
All HDM1005 trials (10)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07417306 | SGLT2 | A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor | P3 | not yet recruiting | 912 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Mar 2026 |
| NCT07394114 | A Study of HDM1005 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone | P3 | recruiting | 240 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Feb 2026 | |
| NCT07521631 | Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes | P2 | recruiting | 372 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Mar 2026 | |
| NCT07502001 | Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin | P1 | not yet recruiting | 42 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Apr 2026 | |
| NCT07279194 | Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes | P3 | recruiting | 825 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Oct 2025 | |
| NCT07559240 | A Pharmacokinetic Study of HDM1005 Injection in Participants With Impaired Renal Function and Healthy Participants | P1 | not yet recruiting | 30 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | May 2026 | |
| NCT07109700 | A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin | P2 | recruiting | 216 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Apr 2025 | |
| NCT06886126 | Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes Mellitus | P2 | recruiting | 240 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Feb 2025 | |
| NCT06637020 | Phase Ib Clinical Study of HDM1005 Injection | P1 | completed | 40 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Jun 2024 | |
| NCT06640647 | Phase Ia Clinical Study of HDM1005 Injection | P1 | completed | 65 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Mar 2024 |
HDM1005 clinical trials: frequently asked questions
- How many HDM1005 clinical trials are there?
- 10 HDM1005 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 5 are actively recruiting participants. 2 are marked completed.
- Are HDM1005 clinical trials recruiting in 2026?
- Yes — 5 HDM1005 trials are actively recruiting in 2026. See the recruiting trials and the per-state site list further down this page.
- What conditions is HDM1005 being studied for?
- HDM1005 is being studied for Obesity, Type 2 Diabetes, Overweight, Overweight and Obesity, Obesity and Overweight and 2 more. The trials are grouped by indication on this page.
- What phase is HDM1005 in?
- HDM1005 clinical trials span 3 Phase 3, 3 Phase 2, 4 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors HDM1005 clinical trials?
- The lead sponsor across the most HDM1005 trials is Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming HDM1005as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: